Hinge Health Inc is a technology platform for individuals seeking to treat and prevent joint and muscle pain... Show more
Hinge Health operates a technology platform focused on musculoskeletal (MSK) care — the muscles, bones, and joints — spanning acute injury, chronic pain, and post-surgical rehabilitation. Its core differentiation lies in automating care delivery through artificial intelligence and motion-tracking technology, combined with a proprietary wearable device, while selling primarily to self-insured employers and health plans. This enterprise model creates recurring, ratable revenue and high switching costs, evidenced by management's reported 100% health-plan retention and a client base that grew roughly 28% year over year to about 3,270 contracted clients.
The most consequential strategic shift is the company's evolution from a single-condition MSK provider into a broader digital-health platform. Early traction in Migraine Care — now reaching millions of covered lives across hundreds of clients — and the August 2026 acquisition of Cylinder Health position Hinge Health to cross-sell additional clinical programs to the same employers. This "land-and-expand" strategy is central to the medium-term outlook, because it raises revenue per client without requiring entirely new customer acquisition.
The clearest near-term catalysts are quarterly earnings releases and guidance updates. Hinge Health has demonstrated a pattern of beating consensus and raising the bar, most recently lifting full-year 2026 revenue guidance to roughly $879–$881 million (about 50% growth at the midpoint) and non-GAAP operating-income guidance to approximately $266–$268 million. Sustaining that trajectory into 2027 will depend on continued growth in billings — which management and analysts track as a leading indicator — and on enrollment yield across its expanding product set.
Analyst activity has turned notably more constructive. Following third-quarter results, Needham raised its price target from $115 to $135, Stifel from $130 to $135, Canaccord Genuity from $105 to $134, Raymond James from $92 to $138, and RBC Capital from $110 to $135, all while maintaining "Buy" ratings. S&P Global's consensus points to an average price target around $135, reflecting broad optimism. Product milestones — such as the formal launch of the GI Care Program and the continued rollout of Migraine Care — alongside any additional acquisitions or partnerships, represent further catalysts that could reshape expectations.
Hinge Health's trajectory is tightly linked to employer healthcare economics. Persistently elevated medical costs push self-insured employers toward solutions that reduce musculoskeletal spending, a structural tailwind for value-based digital-health vendors. Demographic shifts, including an aging workforce with rising rates of joint and back conditions, reinforce long-term demand.
On the macro side, interest rates matter in two ways. First, higher rates can pressure corporate benefit budgets during economic softening. Second, as a high-growth, cash-generating SaaS business, Hinge Health's valuation multiple is sensitive to shifts in the broader discount-rate environment. A more favorable inflation and rate backdrop in 2026 has generally supported growth-equity valuations, but any reversal could compress sentiment. Regulatory developments around digital therapeutics and AI in healthcare also represent an evolving factor to monitor.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders assess whether a stock, exchange-traded fund (ETF), or other asset may move bullish, bearish, or sideways over the next week or month. It is designed to help users identify developing trends, evaluate possible breakouts or reversals, and explore predictions across a broad range of tradable instruments. The platform includes searchable prediction categories, historical context, and alert-oriented functionality to support ongoing monitoring. For investors tracking Hinge Health's momentum, the Trend Prediction Engine offers a systematic way to complement fundamental analysis with data-driven directional signals.
Heading into 2026 and beyond, Hinge Health's outlook hinges on several structural drivers. The expansion from MSK into GI and migraine care represents the most significant long-term opportunity, potentially multiplying the company's total addressable market while deepening relationships with existing clients. Management's emphasis on "yield" — the share of eligible members who enroll and engage — suggests a focus on monetizing its installed base rather than relying solely on new logos.
Margin sustainability is another key theme. The company's improving gross margin, positive free cash flow, and rising operating leverage signal a maturing cost structure, but continued investment in new clinical programs could temper near-term profitability. Competitive threats from larger healthcare incumbents and well-funded digital-health rivals remain a consideration, as does the premium valuation the stock commands relative to peers. Consensus analyst expectations remain optimistic, but much of that optimism now prices in successful execution across unproven product categories. As a result, the company's ability to convert platform expansion into tangible, sustained revenue will likely be the defining factor shaping investor sentiment through 2026 and into 2027.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| EQL | 51.78 | -0.66 | -1.26% |
| Alps Equal Sector Weight ETF (EQL) | |||
| STEN | 27.82 | -0.42 | -1.48% |
| iShares Large Cap 10% Target Buffer Sep ETF (STEN) | |||
| XLC | 106.82 | -1.87 | -1.72% |
| State Street Communication Services Select Sector SPDR ETF (XLC) | |||
| FDTS | 65.19 | -1.15 | -1.73% |
| First Trust Developed Markets ex-US Small Cap AlphaDEX Fund (FDTS) | |||
| BDEC | 53.05 | -1.00 | -1.85% |
| Innovator U.S. Equity Buffer ETF - December (BDEC) | |||
A.I.dvisor indicates that over the last year, HNGE has been loosely correlated with TDOC. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if HNGE jumps, then TDOC could also see price increases.
| Ticker / NAME | Correlation To HNGE | 1D Price Change % | ||
|---|---|---|---|---|
| HNGE | 100% | +5.11% | ||
| TDOC - HNGE | 36% Loosely correlated | -1.14% | ||
| TEM - HNGE | 35% Loosely correlated | -9.55% | ||
| VEEV - HNGE | 33% Loosely correlated | -0.75% | ||
| DOCS - HNGE | 33% Loosely correlated | -1.71% | ||
| EVH - HNGE | 31% Poorly correlated | -1.43% | ||
More | ||||
| Ticker / NAME | Correlation To HNGE | 1D Price Change % |
|---|---|---|
| HNGE | 100% | +5.11% |
| Services to the Health Industry industry (41 stocks) | 16% Poorly correlated | -3.10% |
| Health Services industry (238 stocks) | 3% Poorly correlated | -2.84% |
Industry ServicestotheHealthIndustry
HNGE saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 13, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 12 instances where the indicator turned negative. In 11 of the 12 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The 10-day RSI Indicator for HNGE moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 8 similar instances where the indicator moved out of overbought territory. In 4 of the 8 cases, the stock moved lower in the following days. This puts the odds of a move lower at 50%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 12 of 15 cases where HNGE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HNGE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
HNGE broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Following a +6.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where HNGE advanced for three days, in 82 of 96 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Aroon Indicator entered an Uptrend today. In 71 of 80 cases where HNGE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 25 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. HNGE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: HNGE's P/B Ratio (27.129) is slightly higher than the industry average of (4.523). P/E Ratio (14.015) is within average values for comparable stocks, (12.601). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (10.504) is also within normal values, averaging (6.105).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HNGE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.